BIOVECTRA is now ready to accept projects at its manufacturing facility in Windsor, NS, Canada, for its new, single-use biologics fermentation suite. Containing 100 L and 1,000 L single-use fermenters, this state-of-the-art process train enhances the contract development and manufacturing organization (CDMO)’s microbial fermentation overall capacity. It also allows the company to support even more promising biologics for their tech-transfer and optimization, early and mid-stage clinical investigation, along with commercial scale supply of highly specialized therapeutics.
The addition of single-use fermentation capability provides BIOVECTRA customers with several benefits, such as more flexibility, faster turnaround times, and increased capacity utilization. Additional advantages include a decreased risk of contamination, and the elimination of costly and time-consuming cleaning and sterilization between batches.
“Our closed, sterile single-use fermenters are designed to provide mixing, oxygen transfer, and cooling capabilities comparable to stainless-steel bioreactors, while being more agile and avoiding their fixed costs, which is a benefit many of our clients are eager to explore,” comments Heather Delage, BIOVECTRA’s chief commercial officer. “ … Companies that want to start a clinical program and take it to commercial launch are no longer faced with an either/or choice of single-use versus stainless-steel fermenters,” Delage continues. “The combination of the two can be ideal for those engaged in clinical-to-commercial scale production.”
Read more about the CDMO’s expansion of services here.